Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
about
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerAnticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stressTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyImmunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translationCombinatorial strategies for the induction of immunogenic cell death.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removalStimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cellsAutophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell deathImmature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer ImmunityER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses.Photodynamic Therapy and Its Role in Combined Modality Anticancer Treatment.Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.Autophagy, a major adaptation pathway shaping cancer cell death and anticancer immunity responses following photodynamic therapy.The Role of Damage-Associated Molecular Patterns (DAMPs) in Human Diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine.DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing.Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysisConsensus guidelines for the detection of immunogenic cell death.Melanoma targeting with the loco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeutic efficacyPhysical modalities inducing immunogenic tumor cell death for cancer immunotherapy.Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.Trial watch: Dendritic cell-based anticancer immunotherapy.Trial Watch: Chemotherapy with immunogenic cell death inducers.Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy
P2860
Q26795466-0F44B7AD-CB96-4F22-B09B-FCEB283C2342Q26799265-D290D64E-5224-4F07-B8F9-F007FB199BC4Q27004011-9FDFC1D9-3E2B-4DC7-BC60-A43AE5DD4EC8Q28386858-E36AE1BB-BE23-43C1-99FD-28125D99CCC4Q35535140-1B68B305-AE1A-41D7-BF4D-A0828A8C9C63Q36301061-7C3C9D41-A0E6-414F-90FC-9507D706F571Q36413628-289A9403-3801-4B12-9C6F-8D9BB2716288Q36689078-8954984B-1B31-4E32-A34D-4A4074414EABQ37701461-D11E875E-F7A2-4AE8-B651-AC24BF05EECBQ37745133-3ABB963C-B488-470B-A1C9-F0B3D68EBC12Q38174601-8E2D68C3-2246-496F-96F1-F29D725E6133Q38184935-5546A196-1FA7-4F16-8D26-BEC618D701C0Q38265889-7AD70D40-AB3E-43B1-8580-005E34FF78F5Q38284345-C3DE4042-DC6E-4303-A512-AEA614C0F078Q38349813-60B36588-3AD9-4AD7-8766-0E5E992A0E10Q38519934-ABB676AA-6976-4B54-9B8C-2DB9A306D4C6Q38928826-EAC29EB0-7819-4699-8FFF-A34A54043F08Q39281286-B740BF0A-AF91-4277-87E0-65BDE3B1BB75Q42553556-83A00F4B-05D8-446A-A8FD-73735F141892Q42613506-75F6BCC9-EC56-42EE-962A-D3C5E7A42E73Q43179865-3BB3779C-0B7B-4F6C-88D6-2C18F1ED7849Q47614555-61F047E3-194F-4B16-A854-ECF268AFD2DAQ53109846-95F88DC0-A617-4735-939E-DEC533D0BEB9Q55260834-0063C2B5-1C0A-4EBF-81D0-20818852EF4EQ58729712-CCC78D00-B13F-4645-84F4-58965871EAA6
P2860
Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
@en
type
label
Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
@en
prefLabel
Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
@en
P2093
P2860
P356
P1433
P1476
Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?
@en
P2093
Abhishek D Garg
Aleksandra M Dudek
Patrizia Agostinis
P2860
P304
P356
10.1002/BIOF.1125
P577
2013-07-31T00:00:00Z